Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lonza : Launches SimpliFiH Services an Integrated First-in-Human Service Package for Poorly Soluble Small Molecules

share with twitter share with LinkedIn share with facebook
share via e-mail
05/01/2019 | 11:00am EDT

Basel - Lonza Pharma and Biotech announced the launch of SimpliFiHTM Services, integrating its leading expertise in addressing bioavailability challenges with drug substance, solid-state characterization and drug product for first-in-human studies.

As drug discovery and development accelerate and solubility and dissolution rate challenges become more complex, new solutions are required to reduce the timeline from initial idea to a first-in-human clinical verification.

Lonza's new service package has been specifically designed for innovator companies that have solubility-challenged molecules and require drug substance and drug product services for early-stage development and first-in-human studies. Streamlined service agreement templates specific to the SimpliFiH package have also been developed to further reduce time, cost and complexity for these studies. This new offering demonstrates Lonza's continued commitment to constant innovation and adding value for its customers.

The foundation of SimpliFiH Services is the company's proprietary bioavailability enhancement technology selection methodology. This methodology encompasses databases and models based on more than 25 years' experience advancing thousands of molecules to phase I across all key enabling technologies - particle size reduction, solid dispersions and lipid-based formulations. By using this methodology, a single enabling approach for early first-in-human studies can be rapidly identified without extensive solubility screening which thereby reduces early phase clinical timelines and API requirements.

SimpliFiH Services encompasses the key drug substance and drug product components required for first-in-human studies for small molecules: drug substance development and supply, solid-state characterization/bioavailability enhancement, and phase-appropriate drug product in powder-in-capsule, powder-in-bottle, liquid-filled hard capsule or tablet format.

Basic analytical services inclusive of stability studies are included in the SimpliFiH Services package. Regulatory services for supporting, consulting on or writing IND and IMPD are available to support first-in-human requirements.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.


Dirk Oehlers

Tel: +41 61 316 8540

Email: dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LONZA GROUP
09/10LONZA : Announces Refinancing Extension and Increase of Its Term and Revolving B..
09/10LONZA : Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiti..
09/03CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
08/15LONZA : Highlights Cutting-Edge Clean-Label Solutions to Welcome a Healthy Futur..
08/08LONZA : Welcomes Healthy Future for Brazilian Dietary Supplements Market at Fi S..
08/01Blue-blooded crabs at heart of pharma dispute on drug testing
07/24Lonza on Track to Deliver Full-Year 2019 Results, Driven by Pharma Biotech Bu..
07/24Lonza Expands Bioconjugation Facility and Announces Approval of Third Commerc..
07/11LONZA : Showcases Innovative Solutions to Make More Possible at the 14th Interna..
More news
Financials (CHF)
Sales 2019 5 906 M
EBIT 2019 1 205 M
Net income 2019 732 M
Debt 2019 3 247 M
Yield 2019 0,85%
P/E ratio 2019 34,3x
P/E ratio 2020 28,7x
EV / Sales2019 4,81x
EV / Sales2020 4,44x
Capitalization 25 147 M
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 372,92  CHF
Last Close Price 338,70  CHF
Spread / Highest target 36,4%
Spread / Average Target 10,1%
Spread / Lowest Target -18,8%
EPS Revisions
Richard Ridinger Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP32.98%25 321
CELLTRION, INC.--.--%18 395